Fig. 1 (abstract P422).From: 32nd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017): Part TwoOverall Survival for Patients with Stage IV NSCLC, From Initial Diagnosis of Advanced or Metastatic NSCLCBack to article page